Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 9/20 | 1.00 |
| ▸ | PPARG | P37231 | 2/20 | 0.57 |
| ▸ | PPARA | Q07869 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.51 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.51 |
| ▸ | TTR | P02766 | 2/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18058921 | 0.87 | FFAR1 (0.78) | FFAR1PPARGPPARAFFAR4SRD5A2 | |
| SCHEMBL9036833 | 0.85 | FFAR1 (0.74) | FFAR1TDP1MRGPRX4TTRCHRM1 | |
| SCHEMBL8332044 | 0.83 | FFAR1 (0.71) | FFAR1PPARGPPARATDP1MRGPRX4 | |
| SCHEMBL18058920 | 0.83 | FFAR1 (1.00) | FFAR1PPARGPPARATDP1MRGPRX4 | |
| SCHEMBL8104954 | 0.82 | FFAR1 (0.70) | FFAR1TDP1MRGPRX4FFAR4TTR | |
| SCHEMBL28927554 | 0.82 | FFAR1 (0.69) | FFAR1PPARGPPARAFFAR4CHRM1 | |
| SCHEMBL30172602 | 0.82 | FFAR1 (0.69) | FFAR1PPARGPPARAFFAR4CHRM1 | |
| SCHEMBL2171471 | 0.79 | FFAR1 (0.65) | FFAR1TTR | |
| SCHEMBL9272097 | 0.78 | FFAR1 (0.64) | FFAR1TDP1MRGPRX4TTRCHRM1 | |
| SCHEMBL15211124 | 0.78 | FFAR1 (0.72) | FFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118085061-A | Cyclic peptide tyrosine compounds as neuropeptide y receptor modulators | 詹森药业有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-110099692-B | Cyclic peptide tyrosine compounds as neuropeptide y receptor modulators | 詹森药业有限公司 | 2024-03-12 | — | — | CN | disclosed |
| US-20160257701-A1 | NOVEL HETEROCYCLIC COMPOUNDS | CADILA HEALTHCARE LIMITED (IN) | 2016-09-08 | — | — | US | disclosed |
| US-20110124503-A1 | NOVEL HERBICIDE RESISTANCE GENES | DOW AGROSCIENCES LLC (US) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124503-A1 | NOVEL HERBICIDE RESISTANCE GENES | ALDH7A1, AGXT, AADAC | FFAR1 1753/4885PPARG 912/4885PPARA 2256/4885 |
| US-20160257701-A1 | NOVEL HETEROCYCLIC COMPOUNDS | GPR55, GPR68, GPR65 | FFAR1 23/4885PPARG 70/4885PPARA 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.